The 100 best performing ASX stocks in FY21 msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
These 3 ASX biotech shares are all up at least 120% in a year
These 3 biotech shares have gone gangbusters across the past 12 months.
Multi Asset Portfolio Strategist at Zecca Capital Partners
Zach is a hedge fund analyst with an extensive background in equities and portfolio management. Alongside to contributing The Motley Fool, he works in portfolio strategy with a multi-asset and multi-strategy hedge fund manager. As such, he has a unique approach to research and investing, taking a top town approach to identify unique value propositions that sit within his circle of competence. Zach enjoys the more foolish things in life, in addition to Rugby.
Switzer Daily
19 May 2021
The IIR Pharma & Biotech Index performed well in April, up 6.2% Month-on-Month (MoM). This was above the ASX All Ordinaries Accumulation Index and the ASX Small Ordinaries Accumulation Index which were up 3.9% and 5.0% MoM, respectively.
Of the 140 companies in the IIR Pharma & Biotech Index, only 38 companies have a negative share price return over the 12-months to 30 April 2021 and 48 companies have a share price return of 100% or more.
ADO makes top 10
Anteotech Ltd (ASX: ADO) made its way into the top 10 constituents in April after the share price increased 74% for the month. The market cap of ADO has increased from $37.8 m to $815.3 m over the 12-months to April-end. We note that post month-end, the share price has weakened on the back of a capital raising at a significant discount.